The $54 per share price is 50 percent higher than SonoSite's three-month average closing price, and 75 percent higher than the stock price before rumblings of a sale were published in early November. The acquisition will combine Fujifilm's diagnostic medical imaging and SonoSite's point-of-care and miniaturization expertise, according to the vendors.
SonoSite's products are used in more than 20 medical specialties. The vendor will have access to Fujifilm's worldwide sales and distribution channels. SonoSite will become a wholly owned subsidy of Fujifilm and remain in Bothell, Wash., with current leadership at the helm.
Be the first to comment on this post using the section below.